Abstract
Patient was a 62 years old woman with invasive ductal carcinoma of the right breast, treated with lumpectomy and chemotherapy with doxorubicin. Three years later, she presented with exertional shortness of breath, NYHA class II. Echocardiogram revealed severely enlarged left ventricle and ejection fraction of 15% by 3D echocardiogram. She had normal coronary angiogram. She was diagnosed with dilated cardiomyopathy, secondary to doxorubicin treatment. She was started on guideline-directed medical therapy and after 3 months, LV EF improved to 32%, ramipril then switched to Sacubitril/valsartan (Entresto) and she underwent ICD insertion for primary prevention. On 2 years follow up, she was stable and euvolemic however still with LVEF of 34%.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.
Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938–45.
McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75.
ipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525–33.
Reichardt P, Tabone MD, Mora J, Morland B, Jones RL. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018;14(25):2663–76.
Lipshultz SE. Letter by Lipshultz regarding article, “anthracycline cardiotoxicity: worrisome enough to have you quaking?”. Circ Res. 2018;122(7):e62–3.
Lipshultz SE, Herman EH. Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovasc Res. 2018;114(2):205–9.
Choi HS, Park ES, Kang HJ, Shin HY, Noh CI, Yun YS, et al. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. J Korean Med Sci. 2010;25(9):1336–42.
Ganatra S, Nohria A, Shah S, Groarke JD, Sharma A, Venesy D, et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology. 2019;5(1):1.
Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, et al. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J. 2019;40(48):3913–20.
Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097breast cancer patients. J Natl Cancer Inst. 2008;100:1058–67.
Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.
Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S, Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. South Med J. 2007;100:262–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rohani, A. (2021). Doxorubicin Induced Heart Failure with Reduced Ejection Fraction. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-71155-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71154-2
Online ISBN: 978-3-030-71155-9
eBook Packages: MedicineMedicine (R0)